MA38679B1 - Modulateurs du récepteur de cxcr7 - Google Patents
Modulateurs du récepteur de cxcr7Info
- Publication number
- MA38679B1 MA38679B1 MA38679A MA38679A MA38679B1 MA 38679 B1 MA38679 B1 MA 38679B1 MA 38679 A MA38679 A MA 38679A MA 38679 A MA38679 A MA 38679A MA 38679 B1 MA38679 B1 MA 38679B1
- Authority
- MA
- Morocco
- Prior art keywords
- cxcr7
- modulators
- receiver modulators
- formula
- receiver
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Liquid Crystal Substances (AREA)
Abstract
L'invention concerne des dérivés de formule (i), dans laquelle (r1)n, r 2a, r 2b, r 3a, r 3b, r 4, l1, l2, x, y et ar1 sont tels que définis dans la description, ainsi que leur préparation, des sels pharmaceutiquement acceptables de ceux-ci et leur utilisation en tant que produits pharmaceutiques, des compositions pharmaceutiques contenant au moins un composé de formule (i), et en particulier leur utilisation en tant que modulateurs du récepteur de cxcr7
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2013054478 | 2013-05-30 | ||
| PCT/IB2014/061774 WO2014191929A1 (fr) | 2013-05-30 | 2014-05-28 | Modulateurs du récepteur de cxcr7 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38679A1 MA38679A1 (fr) | 2018-07-31 |
| MA38679B1 true MA38679B1 (fr) | 2019-12-31 |
Family
ID=50943357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38679A MA38679B1 (fr) | 2013-05-30 | 2014-05-28 | Modulateurs du récepteur de cxcr7 |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US9920010B2 (fr) |
| EP (1) | EP3004082B1 (fr) |
| JP (1) | JP6393749B2 (fr) |
| KR (1) | KR102302580B1 (fr) |
| CN (1) | CN105263924B (fr) |
| AR (1) | AR096490A1 (fr) |
| AU (1) | AU2014272718B2 (fr) |
| BR (1) | BR112015030095B1 (fr) |
| CA (1) | CA2912133C (fr) |
| CL (1) | CL2015003470A1 (fr) |
| CY (1) | CY1119537T1 (fr) |
| DK (1) | DK3004082T3 (fr) |
| EA (1) | EA028604B1 (fr) |
| ES (1) | ES2645470T3 (fr) |
| HK (1) | HK1223353A1 (fr) |
| HR (1) | HRP20171597T1 (fr) |
| HU (1) | HUE036649T2 (fr) |
| IL (1) | IL242782B (fr) |
| LT (1) | LT3004082T (fr) |
| MA (1) | MA38679B1 (fr) |
| MX (1) | MX364104B (fr) |
| MY (1) | MY173564A (fr) |
| NO (1) | NO3004082T3 (fr) |
| PH (1) | PH12015502632A1 (fr) |
| PL (1) | PL3004082T3 (fr) |
| PT (1) | PT3004082T (fr) |
| SG (1) | SG11201509057UA (fr) |
| SI (1) | SI3004082T1 (fr) |
| TW (1) | TWI640510B (fr) |
| UA (1) | UA118562C2 (fr) |
| WO (1) | WO2014191929A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR091516A1 (es) | 2012-06-22 | 2015-02-11 | Actelion Pharmaceuticals Ltd | Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida |
| JP6582056B2 (ja) | 2014-12-01 | 2019-09-25 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | Ｃｘｃｒ７受容体調節剤 |
| WO2017070431A1 (fr) * | 2015-10-23 | 2017-04-27 | James Merritt | Utilisation d'antagonistes de ccr1 en tant que traitement de tumeurs du système nerveux central |
| AU2017302079B2 (en) * | 2016-07-28 | 2021-07-22 | Idorsia Pharmaceuticals Ltd | Piperidine CXCR7 receptor modulators |
| LT3625228T (lt) | 2017-05-18 | 2021-10-25 | Idorsia Pharmaceuticals Ltd | Pirimidino dariniai, kaip pge2 receptoriaus moduliatoriai |
| HUE056080T2 (hu) | 2017-05-18 | 2022-01-28 | Idorsia Pharmaceuticals Ltd | Fenilszármazékok mint PGE2 receptor modulátorok |
| BR112020015024A2 (pt) | 2018-01-26 | 2021-01-19 | Idorsia Pharmaceuticals Ltd | Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método de profilaxia ou tratamento de câncer, distúrbios autoimunes, doenças inflamatórias, rejeição a transplante ou fibrose |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3896170A (en) | 1969-02-26 | 1975-07-22 | American Home Prod | Intermediates for the preparation of 1,3-dihydro-2h-1, -benzodiazepin-2-ones |
| EP1071426A2 (fr) | 1998-02-18 | 2001-01-31 | Neurosearch A/S | Nouveaux composes et leur utilisation comme modulateurs positifs du recepteur ampa |
| GB9816984D0 (en) * | 1998-08-05 | 1998-09-30 | Smithkline Beecham Plc | Novel compounds |
| EP1341765A1 (fr) | 2000-12-07 | 2003-09-10 | AstraZeneca AB | Composes therapeutiques |
| ATE427933T1 (de) * | 2002-12-20 | 2009-04-15 | Chemocentryx Inc | Inhibitoren der bindungder chemokine i-tac bzw. sdf-1 an den ccxckr2-rezeptor |
| WO2007059108A2 (fr) * | 2005-11-10 | 2007-05-24 | Chemocentryx, Inc. | Quinolones substituees et procedes d'utilisation |
| US20100331298A1 (en) | 2007-12-10 | 2010-12-30 | Cytopathfinder, Inc. | Carboxamide Compounds and Their Use |
| AR091516A1 (es) * | 2012-06-22 | 2015-02-11 | Actelion Pharmaceuticals Ltd | Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida |
| JP6582056B2 (ja) | 2014-12-01 | 2019-09-25 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | Ｃｘｃｒ７受容体調節剤 |
-
2014
- 2014-05-28 JP JP2016516287A patent/JP6393749B2/ja active Active
- 2014-05-28 BR BR112015030095-2A patent/BR112015030095B1/pt active IP Right Grant
- 2014-05-28 HU HUE14730591A patent/HUE036649T2/hu unknown
- 2014-05-28 UA UAA201512741A patent/UA118562C2/uk unknown
- 2014-05-28 WO PCT/IB2014/061774 patent/WO2014191929A1/fr active Application Filing
- 2014-05-28 EA EA201501163A patent/EA028604B1/ru not_active IP Right Cessation
- 2014-05-28 SI SI201430415T patent/SI3004082T1/sl unknown
- 2014-05-28 AU AU2014272718A patent/AU2014272718B2/en active Active
- 2014-05-28 SG SG11201509057UA patent/SG11201509057UA/en unknown
- 2014-05-28 ES ES14730591.6T patent/ES2645470T3/es active Active
- 2014-05-28 CN CN201480030766.2A patent/CN105263924B/zh active Active
- 2014-05-28 LT LTEP14730591.6T patent/LT3004082T/lt unknown
- 2014-05-28 PL PL14730591T patent/PL3004082T3/pl unknown
- 2014-05-28 NO NO14730591A patent/NO3004082T3/no unknown
- 2014-05-28 MX MX2015016429A patent/MX364104B/es active IP Right Grant
- 2014-05-28 CA CA2912133A patent/CA2912133C/fr active Active
- 2014-05-28 KR KR1020157036801A patent/KR102302580B1/ko active IP Right Grant
- 2014-05-28 US US14/892,959 patent/US9920010B2/en active Active
- 2014-05-28 MY MYPI2015704311A patent/MY173564A/en unknown
- 2014-05-28 MA MA38679A patent/MA38679B1/fr unknown
- 2014-05-28 DK DK14730591.6T patent/DK3004082T3/en active
- 2014-05-28 PT PT147305916T patent/PT3004082T/pt unknown
- 2014-05-28 EP EP14730591.6A patent/EP3004082B1/fr active Active
- 2014-05-29 AR ARP140102121A patent/AR096490A1/es active IP Right Grant
- 2014-05-29 TW TW103118884A patent/TWI640510B/zh not_active IP Right Cessation
-
2015
- 2015-11-25 IL IL242782A patent/IL242782B/en active IP Right Grant
- 2015-11-26 PH PH12015502632A patent/PH12015502632A1/en unknown
- 2015-11-27 CL CL2015003470A patent/CL2015003470A1/es unknown
-
2016
- 2016-10-04 HK HK16111524.4A patent/HK1223353A1/zh unknown
-
2017
- 2017-10-18 HR HRP20171597TT patent/HRP20171597T1/hr unknown
- 2017-11-02 CY CY20171101149T patent/CY1119537T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45782B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
| MA38679B1 (fr) | Modulateurs du récepteur de cxcr7 | |
| MA37400B1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
| MA42230B1 (fr) | Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant | |
| MA42678B1 (fr) | Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5 | |
| MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA42231B1 (fr) | Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant | |
| MA35749B1 (fr) | Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc | |
| MY169986A (en) | Benzimidazole-proline derivatives | |
| MA43251B1 (fr) | Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2 | |
| MA49127B1 (fr) | Dérivés d'indole n-substitués | |
| MA37142A3 (fr) | Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine | |
| MA35893B1 (fr) | Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7 | |
| MA39165A1 (fr) | Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires | |
| MA38854B1 (fr) | Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique | |
| MA38410A1 (fr) | Composés d'azétidinyloxyphénylpyrrolidine | |
| MA40366A (fr) | Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines | |
| EA201490573A1 (ru) | Соединение бензотиазолона | |
| MA44965A (fr) | Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3 | |
| MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
| IN2014MN02433A (fr) | ||
| MA35010B1 (fr) | Inhibiteurs de la peptide déformylase | |
| MA37879B1 (fr) | Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant | |
| MX2015012575A (es) | Novedosos derivados de acrilamida como agentes contra la malaria. | |
| EA201490342A1 (ru) | Производные пиразолина и их применение в качестве селективных модуляторов рецептора андрогена |